Crossmark

Methodological considerations in sacituzumab govitecan meta-analysis for metastatic triple-negative breast cancer

Published Online: 2026-03-30

Published Print: 2026-04

Authors

Altundag, Kadri
License Information

Text and Data Mining valid from 2026-03-30

Version of Record valid from 2026-03-30
More Information

Article History

Received: 19 January 2026

Accepted: 21 March 2026

First Online: 30 March 2026

Declarations

:

: The authors declare no competing interests.

Free to read: This content has been made available to all.

Document is current